Physician profile
Babrak Carvan
NPI 1063585180
$503.29
in general payments reported to CMS, 2019-2025
14 companies · $117 in 2025
The $117 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.93 · 2020: $32.00 · 2021: $46.32 · 2022: $18.41 · 2023: $149 · 2024: $121 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $155.97 | 2019-2025 | Verquvo, Steglatro |
| Janssen Pharmaceuticals, INC | $81.99 | 2024 | Xarelto |
| Exact Sciences Corporation | $33.27 | 2023 | Cologuard Collection Kit |
| Abiomed | $25.92 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.77 | 2025 | Jardiance |
| Novo Nordisk INC | $23.81 | 2021 | |
| Boston Scientific Corporation | $22.68 | 2024 | Watchman Flx |
| Amarin Pharma, INC. | $22.51 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.44 | 2023 | Gattex |
| Alk-Abello, INC | $20.94 | 2025 | Neffy |
| Esperion Therapeutics, INC. | $18.51 | 2023 | Nexletol |
| Abbott Laboratories | $18.41 | 2022 | |
| Lilly USA, LLC | $16.74 | 2024 | Mounjaro |
| Sanofi Pasteur INC. | $15.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babrak Carvan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.